Isabelle Desmoulins

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Hervé Bonnefoi, Thomas Grellety, Olivier Trédan et al. · Annals of Oncology · 2016 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Paul Cottu, Véronique D’Hondt, Sylvain Dureau et al. · Annals of Oncology · 2018 · 170 citations · Full text

Medicine, Oncology, Pharmacology +15

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

Thomas Grinda, Alison Antoine, William Jacot et al. · ESMO Open · 2021 · 134 citations · Full text

Medicine, Oncology, Breast Oncology +12

Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study

Gaëtan Chanteloup, Marine Cordonnier, Nicolás Isambert et al. · Journal of Extracellular Vesicles · 2020 · 108 citations · Full text

Medicine, Molecular Biology, Oncology +16